


Online Adaptive Radiotherapy



Dr. med. Hossein Hemmatazad
Department for Radiation Oncology
Bern University Hospital (Inselspital)

Background



Basic Radiotherapy Physics and Biology pp 307-312

- GTV: gross tumor volume**, defined as visible tumor volume in images
- CTV: clinical target volume**, defined as GTV + subclinical/invisible invasion
- ITV: internal target volume**, defined as CTV + IM (internal margin for organ motion)
- PTV: planning target volume**, defined as ITV + SM (setup margin for setup error)




Ideal world: 100% of radiation dose to PTV and 0% to OARS!


Background




2D-RT



3D-CRT



VMAT




SBRT

Significant improvement in RT techniques!


Is that enough?

Background

POSITION IN THE CT SCAN




POSITION IN THE TREATMENT



Main reasons:

- Mispositionning
- Organ motion
- Change of shape




Is correction always possible with image-guidance???

Background

- Anatomical changes during the course of cancer treatment

M. Kwint et al. / Radiotherapy and Oncology 113 (2014) 392–397



- cT4N2M0 NSCLC
- RT: 24 x 2.75Gy
- Initial atelectasis of left lung
- CBCT of week 3


High risk of tumor undercoverage!

Background

- Tumor shrinkage during the course of cancer treatment

M. Kwint et al. / Radiotherapy and Oncology 113 (2014) 392–397

- PTV
- GTV




- cT4N2M0 NSCLC
- RT: 17 x 3Gy
- CBCT of week 3

High risk of lung toxicity!


Adaptive Radiotherapy (definition)

Changing the RT plan (**re-planning**) in reaction to geometrical/anatomical changes in the patient!

Adaptive Radiotherapy



Adaptive Radiotherapy (offline)



Daily CBCT evaluation of anatomical changes and re-planning when necessary!

Adaptive Radiotherapy (offline)

Review Article

Adaptive Radiation Therapy for Head and Neck Cancer—Can an Old Goal Evolve into a New Standard?



David L. Schwartz¹ and Lei Dong²

¹Department of Radiation Medicine, North Shore-LIJ Health System, 270-05 76th Avenue, New Hyde Park, NY 11040, USA



²Department of Radiation Physics, University of Texas MD Anderson Cancer Center, Unit 94, 1515 Holcombe Blvd., Houston, TX 77030, USA

Correspondence should be addressed to David L. Schwartz, dschwartz3@nshs.edu

Received 8 April 2010; Accepted 21 June 2010



Adaptive Radiotherapy (online)



**Repeat every day
(20-25min)**

Adaptive Radiotherapy (Inselspital)



19.07.2021 Go-live
1st patient with esophageal
cancer (IGRT)





IGRT: Esophageal cancer, rectal
cancer, anal cancer, prostate cancer,
palliative RT



10.01.2022 Go-live
1st patient with esophageal
cancer (ART)

Ethos vs. Truebeam



Treatment planning system	Ethos	Eclipse
Dose calculation algorithm	Acuros XB	AAA (Standard) Acuros XB EMC (Electrons)
IGRT	Daily kV-CBCT mandatory	kV/MV planar kV-CBCT
6D-Couch	No	Yes

Online-ART	Yes	No
Treatment technique		
3DCRT	No	Yes
Gating	No	Yes
IMRT	Yes	Yes
VMAT	Yes	Yes
Beam direction	coplanar only	coplanar non-coplanar
Jaws	No	Yes
MLC	Dual layer MLC	Single layer MLC (MLC120)
Max. Field Size	28 x 38.5 cm ²	40 x 40 cm ²
Particles	Photons	Photons, Electrons
Energies	6 MV	4 – 15 MV (Photons) 6 – 22 MeV (Electrons)
Flattening Filter	FFF	FF (Standard) FFF
Dose Rate	800 MU/min	up to 2400 MU/min

ETHOS: Limitations

- Electron plans: e.g. superficial tumors, Mamma boost
- IGRT plans: Where 6DOF couch is required (H&N, stereotactic radiotherapy)
- 3D (non-modulated) plans
- Gating
- Large volumes in longitudinal direction
- Situations where non-coplanar beam directions are beneficial (e.g. intracranial, radiosurgery)
- Situations where higher photon energies are beneficial (large patients)
- Presence of implants: Truebeam workflow maybe more efficient

Adaptive Radiotherapy





Fig. 2 Workflow comparison between IGRT and adaptive radiotherapy

ART: Resources, Time, Expertise!


Adaptive Radiotherapy



Adaptive Radiotherapy

87 %
of the time, the
adaptive plan is selected

Adaptive Sessions System use per anatomical site



Analysis based on 89 institutions in EMEA, APJL, and Americas from September 2019 through July 31, 2023
*August 2020 data are incomplete

Adaptive Radiotherapy



Guarantee daily PTV coverage



Control daily OAR delivered dose



Dose escalation



Margins reduction



Reduce toxicity

What could be the clinical benefit to personalize the treatment with ART?

Hypothesis: Potential Benefits

Experiences at Inselfpital: Esophageal Cancer

Esophageal cancer: Large volumes

Expert Consensus Contouring Guidelines for Intensity Modulated Radiation Therapy in Esophageal and Gastroesophageal Junction Cancer

Abraham J. Wu, MD,* Walter R. Bosch, DSc,† Daniel T. ...

Radial border
In general, the CTV should include any ... (including any ... a 1-cm margin in all ... from the outer esophageal


... be limited to 0.5 cm into uninvolved liver. Excluding the liver and heart from the CTV entirely is reasonable if robust motion management techniques, such as respiratory

... g or an internal target volume approach, are used to minimize the possibility that a CTV border based on a simulation scan is transgressed during radiation treatment as a result of tumor or organ motion. It was also

nes

... to PTV delineation, the panel recommended the CTV by 0.5 to 1 cm in all directions.

Smaller margins / other techniques?



Esophageal cancer: OARs








Fig. 2. Overview of the performed analyses and its relationships and predictive factors ($V_{\text{mean RV}}$ = mean dose on the right ventricle, MLD = mean lung dose, DM = diabetes Mellitus).

J.C. Beukema et al. / Radiotherapy and Oncology 149 (2020) 222–227



Fig. 2. Overall survival according to (A) radiation-induced cardiac complications (RICC), and (B) radiation-induced pulmonary complications (RIPC).

Could we improve something as radiation oncologists?

Esophageal cancer: RT techniques



3DCRT: 4-field static photons; IMRT: 5-field modulated photons




Received Jan 4, 2012, and in revised form Feb 6, 2012. Accepted for publication Feb 7, 2012




Radiotherapy technique matters!

Esophageal cancer: Motion management

1/3 Brachytherapy



3/3 Brachytherapy



The motion could not be corrected in IGRT mode!

Esophageal cancer: Adaptive RT

An in-silico assessment of the dosimetric benefits of MR-guided radiotherapy for esophageal cancer patients

Mick Boekhoff^{a,*}, Ingmar Defize^{a,b}, Alicia Borggreve^{a,b}, Richard van Hillegersberg^b, Alexis Kotte^a, Jan Lagendijk^a, Astrid van Lier^a, Jelle Ruurda^b, Noriyoshi Takahashi^{a,c}, Gert Meijer^{a,*}

^aDepartment of Radiation Oncology; ^bDepartment of Surgery; and ^cDepartment of Radiation Oncology, Tohoku University






Fig. 2. PTV volumes of IGRT plans (black squares) and MRgRT plans (green circles). Average PTV volume for IGRT plans with CT-based contours and 12 mm margins in AP, LR and CC direction, respectively, was 380 cm³ (black dotted line) and for MRgRT plans with 2 mm axial and 5 mm CC CT-based contours and 12 mm margins the average PTV volume was 194 cm³ (green dashed line). (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)

ART: Considerable dose reduction to OARs!




Esophageal cancer (Inselspital)

- **First 10 patients** receiving oART
- Prescription dose 50.4 Gy in 28 fractions
- Same margin concept as in non-adaptive situation
- **280 fractions**
- **560 manual plan reviews (adaptive vs. scheduled)**
 - mean heart dose, lung $V20_{Gy}$, minimal (=D99%) and coverage (=D95%) CTV & PTV dose
- Duration time of each oART workflow step


Characteristics	Patients (n=10)
Age [years]	72 (35 – 85)
Sex	
Female	3 (30)
Male	7 (70)
Histology	
Adeno-Ca.	8 (80)
SCC	2 (20)
Tumor localization	
Middle esophagus	2 (20)
Lower esophagus	8 (80)
T-Stage	
T2	2 (20)
T3	8 (80)
N-Stage	
N0	3 (30)
N1-2	7 (70)
Treatment concept	
Definitive RCHT	3 (30)
Neoadjuv. RCHT	7 (70)

Esophageal cancer: Adaptive RT (Inselspital)


- **28 min** = median time for whole session (range 14.8 – 43.3min)
- **59%** CTV adaptation by MD necessary after automatic propagation
- **99%** adapted treatment plan selected



Esophageal cancer: Adaptive RT (Inselspital)



Esophageal cancer: Adaptive RT (Inselspital)



Esophageal cancer: Adaptive RT (Inselspital)






Fig. 3: Development of the planning target volume (PTV) size over the period of all 28 oART sessions. Every color represents a patient and the dashed lines represent linear regressions of the corresponding dots. Fraction 0 describes the PTV size before the start of oART, i.e. on the planning

Esophageal cancer (Adaptive RT)



Scheduled plan



Adapted plan





<input checked="" type="checkbox"/> Heart		
1 goal	Scheduled	Adapted
Dmean ≤ 1700 cGy Dmean ≤ 1800 cGy (Dmean ≤ 61 cGy / Fx)	P: 1 57 cGy	57 cGy
		72 cGy
<input checked="" type="checkbox"/> Lung_Total		
1 goal	Scheduled	Adapted
V 2000 cGy ≤ 18.0 % V 2000 cGy ≤ 20.0 % (V 71 cGy ≤ 18.0 % / Fx)	P: 2 11.8% 8.1%	5.4% 8.1%

Esophageal cancer (Adaptive RT)

- 47yr old female patient with GEJ-cancer (T3, N0)






Esophageal cancer: Margin reduction



Experiences at Inselspital: SBRT for adrenal metastases




SBRT/ART for adrenal metastasis

- PTV size > 3cm
- 4D PL-CT
- ITV
- 5-7 fractions
- >10 patients



SBRT/ART for pancreatic cancer

- PTV size > 3cm
- 4D PL-CT
- ITV
- 5-7 fractions
- 2 patients



ART: Challenges and future perspective

- Time, resources and expertise
 - CBCT quality
 - Organ motion management (DIBH, identifier?)
 - Data mining from Ethos
-
- ART for all tumor sites?
 - Oncological outcomes?

Thank you for your attention!

